Drug Discovery Prospect from Untapped Species: Indications from Approved Natural Product Drugs

Feng Zhu1,2,3,4, Xiaohua Ma1,2, Chu Qin3,4, Lin Tao3,4, Xin Liu3, Zhe Shi3, Cun Long Zhang1, Chun Yan Tan1, Yu Zong Chen1,3,4, Yu Yang Jiang1*

1 The Key Laboratory of Chemical Biology, Guangdong Province, Graduate School at Shenzhen, Tsinghua University, Shenzhen, Guangdong, People’s Republic of China, 2 Innovative Drug Research Centre and College of Chemistry and Chemical Engineering, Chongqing University, Chongqing, People’s Republic of China, 3 Bioinformatics and Drug Design Group, Department of Pharmacy, and Center for Computational Science and Engineering, National University of Singapore, Singapore, 4 NUS Graduate School for Integrative Sciences and Engineering, Singapore

Abstract

Due to extensive bioprospecting efforts of the past and technology factors, there have been questions about drug discovery prospect from untapped species. We analyzed recent trends of approved drugs derived from previously untapped species, which show no sign of untapped drug-productive species being near extinction and suggest high probability of deriving new drugs from new species in existing drug-productive species families and clusters. Case histories of recently approved drugs reveal useful strategies for deriving new drugs from the scaffolds and pharmacophores of the natural product leads of these untapped species. New technologies such as cryptic gene-cluster exploration may generate novel natural products with highly anticipated potential impact on drug discovery.

Introduction

High-throughput screening and combinatorial chemistry based drug discovery efforts have not led to the expected drug productivity, raising renewed interest in searching drugs from nature [1]. Various species have been extensively searched in the past [2–4] with few percentage of the identified bioactive natural products carried forward to derive 939 approved drugs [2,5] that are composed of limited number of molecular scaffolds [6]. Natural products have fallen out of favor partly because of technology shift [7], diminishing returns and high rediscovery rates [8,9], and supply and screening problems [1,10]. Although new technologies are expected to overcome some of these problems and enable significantly expanded bioprospecting efforts [1,7,11,12], questions remain unanswered about the prospect of deriving new drugs from untapped species at acceptable return rates.

As part of the efforts in probing these questions, we have recently studied the distribution patterns of nature-derived drugs in phylogenetic trees and shown that drug-productive species tend to be clustered in specific regions of phylogenetic space (drug-productive clusters) with most drugs derived from existing drug-productive families (families that have yielded at least one approved drug) [5]. Further clues to the prospect of deriving drugs from untapped species and the effective drug discovery strategies may be gained from the analysis of approved drugs derived from previously untapped species, particularly those approved in recent decades. In this work, we analyzed the species origins of nature-derived drugs approved in 1991–2010 with respect to those approved in previous decades (1961–1990) to find the exploration trends indicative of future bioprospecting prospect and likely sources of untapped new drug-productive species. We also tracked development histories of several classes of approved nature-derived drugs to reveal effective strategies for deriving new drugs from the bioactive natural products isolated from these species.

While the analysis of the approved drugs may provide useful clues to the drug discovery prospect of untapped species, some aspects of drug discovery prospect may not be fully captured because the approved drugs are different from discovered drugs by the additional commercial and technological considerations. For instance, the pharmaceutical industries have moved away from antibiotics partly because these are less lucrative than drugs for chronic conditions [13]. The exploration of microbial species has been limited by the cost and efficiency of cultivation technologies, with the majority of microbial organisms remain uncultured [14,15]. Therefore, caution needs to be exercised in interpreting the results of our analysis, particularly with the possibility that new technologies that explore cryptic gene-clusters and networks [11,12,16,17], inter-species crosstalk [11,18,19] and high-throughput fermentation [20] may provide significantly expanded molecular scaffolds for natural product drug discovery [15].

Citation: Zhu F, Ma XH, Qin C, Tao L, Liu X, et al. (2012) Drug Discovery Prospect from Untapped Species: Indications from Approved Natural Product Drugs. PLoS ONE 7(7): e39782. doi:10.1371/journal.pone.0039782

Copyright: © 2012 Zhu et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: phacyz@nus.edu.sg (YZC); Jiangyy@sz.tsinghua.edu.cn (YYJ)

These authors contributed equally to this work.
Materials and Methods

A total of 939 nature-derived approved drugs have been found from Newman and Cragg’s seminal work [2] and our own literature search [5]. Their species origins have been identified from comprehensive literature search by using combinations of such keywords as drug name and alternative names, species, natural product and nature, and the search results have been confirmed based on such descriptions as “originates from”, “derived from”, “isolated from”, or “comes from” a species. The corresponding species families of the host species of these drugs are from the NCBI taxonomy database [21]. The approval dates of these drugs were from Newman and Cragg’s work [2] and Drugs@FDA on FDA website (http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm).

Results and Discussion

Table 1 presents the statistics of drugs approved in every five-year period of 1961–2010 (divided into drugs derived from previously untapped and previous drug-productive species respectively), and the statistics of drug-productive species that have produced drugs in each period. There are 46–126 nature-derived drugs approved in every 5-year periods since 1991, 7.1%–14.5% of which are from previously untapped species (i.e. untapped before the specific 5-year period) and these species represent 11.4%–41.7% of the drug-productive species that have yielded approved drugs in 1991–2010. In contrast, there are 26–135 nature-derived drugs in every 5-year period of 1961–1990, 18.0%–62.8% of which are from previously untapped species and these species represent 36.7%–76.2% of the drug-productive species in 1961–1990. While the percentages have been reduced to some extent, the recent trends of substantial percentage of drugs and substantial percentage of drug-productive species being from previously untapped species strongly suggests that the untapped drug-productive species is unlikely near extinction, and future bioprospecting efforts are expected to yield new drugs at comparable levels. This is consistent with an earlier analysis of the largest antibiotic-producing genus Streptomyces which suggests that the new compound discovery rate from the unexplored strains of Streptomyces would not decline for several decades and 15–20 antibiotics would be discovered each year at the 1995 exploration level [9]. It is also consistent with the estimated high antibiotic production frequencies by the untapped strains of the actinomycetes class (5 × 10^5–2 × 10^7 in screening 10^4–10^7 strains) [22].

Table 2 provides the list of the new drug-productive species emerged in 1991–2010 together with the approved drugs derived from these species since the first drug approval. There are 59 new drug-productive species emerged in this period, 33 (55%) of which are from existing drug-productive species families and another 22 (37%) of which are from new species families in existing drug-productive clusters. These suggest a high probability of finding new drug-productive species from existing drug-productive families or new families located in existing drug-productive clusters. This coincides with the reported refocused efforts for finding new antibiotics from new sources in the actinomycetes class and cyanobacteria phylum [22], which cover an existing drug-productive cluster (Actinomycetales cluster) and an existing drug-productive family (Symploca family) respectively [5].

From the time of their first drug approval to the end of 2010, these 59 new drug-productive species have yielded 83 approved drugs, 12 (14.1%) and 14 (16.5%) of which are unmodified natural products and biologics respectively, while the majority (69.4%) of the 59 drugs have been derived from bioactive natural products by semi-synthetic modification, structural mimicking or pharmacophore mapping to overcome problems frequently encountered by bioactive natural products such as weak potency [23], low target selectivity [24], toxicity [25], undesired pharmacokinetic properties [26], and supply issues [27]. Retrospective study of the case histories of several classes of recently approved drugs reveal useful strategies for deriving new drugs from bioactive natural products from untapped species to overcome these frequently encountered problems.

Since the discovery of Paclitaxel [28], extensive efforts have been directed at the search of tubulin interacting anticancer drugs from species other than the tapped taxus species, leading to the identification of a number of natural products from untapped
### Table 2. List of the new drug-productive species emerged in 1991–2010 together with the list of approved drugs derived from each species since the first drug approval, and the corresponding species families and their exploration status at the time of first drug approval.

| New Drug Productive Species Emerged in 1991–2010 (Year of First Drug Approval) | Approved Drugs Derived from the Species (Year of Approval, Target(s), Therapeutic Class, Category of Source) | Species Family (Year of First Drug Approval) | Exploration Status of Species Family at the Time of First Drug Approval |
|---|---|---|---|
| Period of 2001–2010 | Halichondria okadai (2010) | Eribulin (2010, Tubulin, anticancer, ND) | Halichondriidae (2010) | Newly emerged drug productive family inside existing drug productive cluster |
| | Isaria sinclairii (2010) | Fingolimod (2009, Sphingosine-1-phosphate receptor S1PR1, immunosuppression, ND) | Cordycipitaceae (2010) | Newly emerged drug productive family inside existing drug productive cluster |
| | Emericella rugulosa (2007) | Anidulafungin (2001, (1->3)beta-D-glucan synthase, antifungal, ND) | Trichocomaceae (1942) | Existing drug productive family |
| | Sorangium cellulosum (2007) | Ixabepilone (2007, Tubulin, anticancer, ND) | Polyangiaceae (2007) | Newly emerged drug productive family inside existing drug productive cluster |
| | Clitopilus scyphoideus (2007) | Retapamulin (2007, Bacterial ribosome, antibacterial, ND) | Entolomataceae (2007) | Newly emerged drug productive family inside existing drug productive cluster |
| | Ecteinascidia turbinate (2007) | Trabectedin (2007, DNA, anticancer, N) | Perophoridae (2007) | Newly emerged drug productive family inside existing drug productive cluster |
| | Heloderma suspectum (2005) | Enexatide (2005, GLP1R, antidiabetic, ND) | Helodermatidae (2005) | Newly emerged drug productive family inside existing drug productive cluster |
| | Aspergillus fumigatus (2005) | Fumagillin (2005, METAP2, antiparasitic, N) | Trichocomaceae (1942) | Existing drug productive family |
| | Conus geographus (2005) | Omega-conotoxin MVIIA (2005, Voltage-dependent N-type calcium channel, chronic pain relief, N) | Conidae (2005) | Newly emerged drug productive family inside existing drug productive cluster |
| | Conus magus (2005) | Omega-conotoxin MVIIA (2005, Voltage-dependent N-type calcium channel, chronic pain relief, N) | Conidae (2005) | Newly emerged drug productive family inside existing drug productive cluster |
| | Streptomyces filamentosus (2003) | Daptomycin (2003, Bacterial cell membrane, antibacterial, N) | Streptomycetaceae (1946) | Existing drug productive family |
| | Galanthus elwesi (2002) | Galantamine (2002, Acetylcholinesterase, Alzheimer’s disease, N) | Amaryllidaceae (1983) | Existing drug productive family |
| | Galanthus nivalis (2002) | Galantamine (2002, Acetylcholinesterase, Alzheimer’s disease, N) | Amaryllidaceae (1983) | Existing drug productive family |
| | Galanthus woronowii (2002) | Galantamine (2002, Acetylcholinesterase, Alzheimer’s disease, N) | Amaryllidaceae (1983) | Existing drug productive family |
| | Leucojum aestivum (2002) | Galantamine (2002, Acetylcholinesterase, Alzheimer’s disease, N) | Amaryllidaceae (1983) | Existing drug productive family |
| | Narcissus pseudonarcissus (2002) | Galantamine (2002, Acetylcholinesterase, Alzheimer’s disease, N) | Amaryllidaceae (1983) | Existing drug productive family |
| | Cocos nucifera (2002) | Gefitinib (2002, EGFR, anticancer, S/NM), Erlotinib (2004, EGFR, anticancer, S/NM), Sunitinib (2006, VEGFR, anticancer, S/NM), Lapatinib (2007, EGFR and HER2, anticancer, S/NM), Pazopanib (2009, VEGFR, anticancer, S/NM) | Arecaceae (1978) | Existing drug productive family |
| | Spinacia oleracea (2002) | Gefitinib (2002, EGFR, anticancer, S/NM), Erlotinib (2004, EGFR, anticancer, S/NM), Sunitinib (2006, VEGFR, anticancer, S/NM), Lapatinib (2007, EGFR and HER2, anticancer, S/NM), Pazopanib (2009, VEGFR, anticancer, S/NM) | Amaranthaceae (2002) | Newly emerged drug productive family outside existing drug productive cluster |
| | Zea mays (2002) | Gefitinib (2002, EGFR, anticancer, S/NM), Erlotinib (2004, EGFR, anticancer, S/NM), Sunitinib (2006, VEGFR, anticancer, S/NM), Lapatinib (2007, EGFR and HER2, anticancer, S/NM), Pazopanib (2009, VEGFR, anticancer, S/NM) | Poaceae (1984) | Existing drug productive family |
| | Coleophoma empetri (2002) | Micafungin (2002, Beta-(1,3)-Glucan synthase, antifungal, ND) | Coleophoma (2002) | Newly emerged drug productive family outside existing drug productive cluster |
| | Brevibacillus laterosporus (2001) | Gusperimus (2001, Interleukin-2, immunosuppressant, ND) | Paenibacillaceae (1942) | Existing drug productive family |
| | Lentzea albida (2001) | Imatinib (2001, Abl, anticancer, ND), Nilotinib (2007, Abl, anticancer, ND) | Actinosynnemataceae (1971) | Existing drug productive family |
| Period of 1991–2000 | Plectranthus barbatus (1999) | Colforsin daropate (1999, Adenylate cyclase, cardiotonic, ND) | Lamiaceae (1978) | Existing drug productive family |
### Table 2. Cont.

| New Drug Productive Species Emerged in 1991–2010 (Year of First Drug Approval) | Approved Drugs Derived from the Species (Year of Approval, Target(s), Therapeutic Class, Category of Source) | Species Family (Year of First Drug Approval) | Exploration Status of Species Family at the Time of First Drug Approval |
|---|---|---|---|
| Corynebacterium diphtheria (1999) | Denileukin difitox (1999, IL-2R, anticaner, B) | Corynebacteriaceae (1999) | Newly emerged drug productive family inside existing drug productive cluster |
| Lendenfeldia chordodes (1998) | Migliol (1998, Alpha-glucosidase, antibiotic, ND), Miglustat (2003, Glucosylceramide synthase, anti-gaucher's disease, ND) | Thorectidae (1998) | Newly emerged drug productive family inside existing drug productive cluster |
| Morus alba (1998) | Migliol (1998, Alpha-glucosidase, antibiotic, ND), Miglustat (2003, Glucosylceramide synthase, anti-gaucher's disease, ND) | Moraceae (1998) | Newly emerged drug productive family inside existing drug productive cluster |
| Streptomyces toxytricini (1998) | Orlstat (1998, Lipase, antibiotic, ND) | Streptomycetaceae (1946) | Existing drug productive family |
| Citrus bergamia (1997) | Hesperetin (1997, Dihydeptide acyltransferase, anti-cardiovascular disease, N) | Rutaceae (1900) | Existing drug productive family |
| Citrus limon (1997) | Hesperetin (1997, Dihydeptide acyltransferase, anti-cardiovascular disease, N) | Rutaceae (1900) | Existing drug productive family |
| Haementeria officinalis (1997) | Lepirudin (1997, Thrombin, antithrombotic, ND), Bivalirudin (2000, Thrombin, anticoagulation, ND), Hirulog (2000, Thrombin, anticoagulation, ND), Desirudin (2003, Thrombin, deep vein thrombosis, ND) | Glosiphoniidae (1997) | Newly emerged drug productive family inside existing drug productive cluster |
| Hirudo medicinalis (1997) | Lepirudin (1997, Thrombin, antithrombotic, ND), Bivalirudin (2000, Thrombin, anticoagulation, ND), Desirudin (2003, Thrombin, deep vein thrombosis, ND) | Hirudinidae (1997) | Newly emerged drug productive family inside existing drug productive cluster |
| Artemisia dracunculus (1996) | Latanoprost (1996, PFG receptor, antiglaucoma, ND), Bimatoprost (2001, PFG receptor, antiglaucoma, ND), Travoprost (2001, PGF receptor, antiglaucoma, ND) | Asteraceae (1975) | Existing drug productive family |
| Mus musculus (1995) | Edrecolomab (1995, EpCAM, anticancer, B), Dacilizumab (1997, IL-2R, immunosuppressant, B), Palivizumab (1998, Fusion glycoprotein, antiviral, B), Trastuzumab (1998, HER-2, anticancer, B), Alemtuzumab (2001, CD52, anticancer, B), Efalizumab (2003, CD11a subunit of lymphocyte function-associated antigen 1, antipsoriatic, B), Omalizumab (2004, Alpha-4 integrin, anti-inflammatory, B), Tocilizumab (2004, Alpha-4 integrin, anti-inflammatory, B), B), Ranibizumab (2006, VEGF-A, antangiogenic, B) | Muridae (1994) | Newly emerged drug productive family inside existing drug productive cluster |
| Aspergillus unilateralis (1995) | Mycophenolate mofetil (1995, IMPDH2, immunosuppressant, ND), Mycophenolic acid (2003, IMPDH2, immunosuppressant, N) | Trichocomaceae (1942) | Existing drug productive family |
| Byssolchlamys nivea (1995) | Mycophenolate mofetil (1995, IMPDH2, immunosuppressant, ND), Mycophenolic acid (2003, IMPDH2, immunosuppressant, N) | Trichocomaceae (1942) | Existing drug productive family |
| Penicillium bialewiesense (1995) | Mycophenolate mofetil (1995, IMPDH2, immunosuppressant, ND), Mycophenolic acid (2003, IMPDH2, immunosuppressant, N) | Trichocomaceae (1942) | Existing drug productive family |
| Penicillium canum (1995) | Mycophenolate mofetil (1995, IMPDH2, immunosuppressant, ND), Mycophenolic acid (2003, IMPDH2, immunosuppressant, N) | Trichocomaceae (1942) | Existing drug productive family |
| Penicillium fagi (1995) | Mycophenolate mofetil (1995, IMPDH2, immunosuppressant, ND), Mycophenolic acid (2003, IMPDH2, immunosuppressant, N) | Trichocomaceae (1942) | Existing drug productive family |
| Penicillium roqueforti (1995) | Mycophenolate mofetil (1995, IMPDH2, immunosuppressant, ND), Mycophenolic acid (2003, IMPDH2, immunosuppressant, N) | Trichocomaceae (1942) | Existing drug productive family |
| Streptomyces argenteolus subsp. Toyonakensis (1995) | Saquinavir mesylate (1995, HIV-1 protease, anti-virus, 5'-NM), Indinavir sulfone (1996, HIV-1 protease, anti-virus, 5'-NM), Ritonavir (1996, HIV-1 protease, anti-virus, 5'-NM), Nelfinavir mesylate (1997, HIV-1 protease, anti-virus, 5'-NM), Amprenavir (1999, HIV-1 protease, anti-virus, 5'-NM), Lopinavir (2000, HIV-1 protease, anti-virus, 5'-NM) | Streptomycetaceae (1946) | Existing drug productive family |
| Streptomyces testaceus (1995) | Saquinavir mesylate (1995, HIV-1 protease, anti-virus, 5'-NM), Indinavir sulfone (1996, HIV-1 protease, anti-virus, 5'-NM), Ritonavir (1996, HIV-1 protease, anti-virus, 5'-NM), Nelfinavir mesylate (1997, HIV-1 protease, anti-virus, 5'-NM), Amprenavir (1999, HIV-1 protease, anti-virus, 5'-NM), Lopinavir (2000, HIV-1 protease, anti-virus, 5'-NM) | Streptomycetaceae (1946) | Existing drug productive family |
| Camptotheca acuminate (1994) | Irinotecan (1994, DNA topoisomerase I, anticancer, ND), Topotecan Cornaceae (1994) (1996, DNA topoisomerase I, anticancer, ND) | Not applicable | Newly emerged drug productive family outside existing drug productive cluster |
### Table 2. Cont.

| New Drug Productive Species Emerged in 1991-2010 (Year of First Drug Approval) | Approved Drugs Derived from the Species (Year of Approval, Target(s), Therapeutic Class, Category of Source) | Species Family (Year of First Drug Approval) | Exploration Status of Species Family at the Time of First Drug Approval |
|---|---|---|---|
| *Halichondria halichondrin B,* from previously untapped western Pacific sponge species [26,27]. Two compounds, homohalichondrin B and halichondrin B, from previously untapped western Pacific sponge *Halichondra* and *Axinella* have shown strong cytotoxicity and tubulin polymerization inhibitory activities, but faced with supply problems [27]. Subsequent works in deriving simplified and synthetically accessible agents based on the halichondrin B skeleton have led to the discovery of eribulin approved in 2009 [27] (Figure 1). Further efforts have also led to the identification of epothilones, species [26,27]. Two compounds, homohalichondrin B and halichondrin B, from previously untapped western Pacific sponge *Halichondra* and *Axinella* have shown strong cytotoxicity and tubulin polymerization inhibitory activities, but faced with supply problems [27]. Subsequent works in deriving simplified and synthetically accessible agents based on the halichondrin B skeleton have led to the discovery of eribulin approved in 2009 [27] (Figure 1). Further efforts have also led to the identification of epothilones, |
particularly epothilone B, from the previously untapped myxobacterium Sorangium cellulosum species as tubulin interacting anticancer agents with potent cytotoxic activity toward paclitaxel-sensitive and paclitaxel-resistant cells [26]. But these compounds are prone to the inactivation by esterase cleavage, and in an effort of overcoming this problem semisynthetic lactam analogs of epothilone B has been derived which led to the discovery of ixabepilone approved in 2009 [26] (Figure 2).

The identification of BCR-ABL as a key target of chronic myeloid leukemia has prompted extensive efforts in identifying anticancer ABL inhibitor drugs [29]. Design works based on the pharmacophore of a nonselective pan-kinase inhibitor staurospronine from the previously untapped Lentzea albida species have resulted in an EGFR selective inhibitor CGP 52411 [24] and subsequently a potent ABL selective inhibitor CGP 57148 [30]. CGP 57148 has undesired pharmacokinetic properties, which is improved by formulating it with mesylate salt leading to Gleevec, a milestone anticancer kinase inhibitor approved in 2001 [31] (Figure 3).

The identification of HIV-1 protease as a key anti-HIV target has also motivated extensive efforts in identifying HIV-protease inhibitor drugs. Before the start of HIV-1 protease inhibitor projects, pepstatin from previously untapped Streptomyces argenteolus subsp. Toyonakensis and Streptomyces testaceus species has been found to show weak human rennin inhibitory activities, and more potent peptidomimetic human rennin inhibitors have been derived from it by further optimizing binding configuration to better mimicking substrate binding [23]. Based on these works, a series of potent peptidomimetic HIV-protease inhibitors have been designed [32,33], leading to a series of approved anti-HIV drugs Saquinavir, Indinavir, Ritonavir, Nelfinavir, Amprenavir, and Lopinavir in 1995–2000.

In 2001–2011, some new molecular scaffolds have been derived from both previously explored species and previously untapped species. For instance, the 4-anilinoquinazoline scaffold in Gefitin...
nib, Erlotinib and Lapatinib has been derived based on the pharmacophore of a selective kinase inhibitor olomoucine, a semi-synthetic derivative of zeatin from Maize, Cocos nucifera, Spinacia oleracea, and Pisum sativum species that have been previously explored for deriving cardiovascular and anthelmintic agents [34–36]. The 2-phenylaminopyrimidine scaffold in Imatinib and Nilotinib has been derived based on the pharmacophore of a nonselective pan-kinase inhibitor staurosporine from the previously untapped Lentzea alibida species [24,30,31]. During the same period of time, many of the existing molecular scaffolds (those found in nature-derived drugs approved before the period) continue to contribute new approved drugs. Examples are the tetracycline scaffold of Minocycline, Methacycline and Tigecycline approved in 2001 and 2005 respectively, and the steriole scaffold of Falcacitrol and Acetyldigitoxin approved in 2001 and 2002 respectively.

While most of the 2001–2011 approved nature-derived drugs targeting previously-explored pathways, some previously un-targeted pathways have become highly successfully targeted. These are MAPK, ErbB, mTOR, Brc-Abl regulated, and hematopoietic cell lineage pathways targeted by 7, 6, 3, 3 and 3 new drugs respectively. These pathways become successfully targeted partly because of the derivation of selective kinase inhibitory scaffolds based on the pharmacophores of zeatin derivatives [34–36] and staurosporine [24,30,31] etc. Some previously successfully explored pathways continue to be successfully targeted. Specifically, the calcium signaling, insulin signaling, and Toll-like receptor pathways are targeted by 10, 4, and 6 drugs approved before 2001 and 5, 4, and 4 drugs approved during 2001–2011 respectively.

Our analysis suggests that untapped drug-productive species are unlikely to be near extinction, and there is a high probability for finding new drug-productive species in the existing drug-productive families and drug-productive clusters. New technologies that explore cryptic gene-clusters [11], pathways [12,17], inter-species crosstalk [11,18,19] and high-throughput fermentation [20] enable the generation of significantly more diverse groups of novel natural products, which has been anticipated to have some impact on drug productivity from nature. Some of the revolutionary new drugs of novel targets, such as Gleevec and Gefitinib approved in recent years and Saquinavir and Paclitaxel from earlier years, as well as new drugs of existing targets, have been derived from bioactive natural products of previously untapped species. Retrospective analysis of the case histories of these drugs reveals useful strategies for deriving new drugs from these natural sources.

Author Contributions
Conceived and designed the experiments: YZC YYJ FZ. Performed the experiments: FZ XHM CQ LT ZS CYT. Analyzed the data: FZ XHM CQ LT ZS CLZ CYT. Contributed reagents/materials/analysis tools: FZ XHM CQ LT. Wrote the paper: YZC FZ.

Figure 2. The route of deriving Ixabepilone (approved in 2009) from natural product epothilone B.

doi:10.1371/journal.pone.0039782.g002
Figure 3. The route of deriving Gleevec (approved in 2001) from natural product staurosporine. The right hand side shows the pharmacophoric supposition of CGP 57148 and CGP-52411 [37].

doi:10.1371/journal.pone.0039782.g003

References

1. Li JW, Vederas JC (2009) Drug discovery and natural products: end of an era or an endless frontier? Science 325: 161–165.
2. Newman DJ, Cragg GM (2007) Natural products as sources of new drugs over the last 25 years. J Nat Prod 70: 461–477.
3. Tulp M, Bohlin L (2002) Functional versus chemical diversity: is biodiversity important for drug discovery? Trends Pharmacol Sci 23: 225–231.
4. Berly J (2005) Bioactive microbial metabolites. J Antibiot (Tokyo) 58: 1–26.
5. Zhu F, Qiu C, Tao L, Liu X, Shi Z, et al. (2011) Clustered patterns of species origins of nature-derived drugs and clues for future bioprospecting. Proc Natl Acad Sci U S A 108: 12943–12948.
6. Bemis GW, Murcko MA (1996) The properties of known drugs. 1. Molecular frameworks. J Med Chem 39: 2087–2093.
7. Koechlin FE, Carter GT (2005) The evolving role of natural products in drug discovery. Nat Rev Drug Discov 4: 206–220.
8. Tulp M, Bohlin L (2005) Rediscovery of known natural compounds: nuisance or goldmine? Trends Pharmacol Sci 26: 173–177.
9. Watve MG, Tickoo R, Jog MM, Bhole BD (2001) How many antibiotics are produced by the genus Streptomyces? Arch Microbiol 176: 386–390.
10. Harvey AL (1999) Medicines from nature: are natural products still relevant to drug discovery? Trends Pharmacol Sci 20: 196–198.
11. Ichiyama Y, Chang SI, Oakley BR, Wang CC (2011) Recent advances in awakening silent biosynthetic gene clusters and linking orphan clusters to natural products in microorganisms. Curr Opin Chem Biol 15: 137–143.
12. Wilkinson B, Micklefield J (2007) Mining and engineering natural-product biosynthetic pathways. Nat Chem Biol 3: 379–386.
13. Projan SJ (2005) Why is big Pharma getting out of antibacterial drug discovery? Curr Opin Microbiol 6: 427–430.
14. Rappe MS, Giovannoni SJ (2003) The uncultured microbial majority. Annu Rev Microbiol 57: 369–394.
15. Piel J (2011) Approaches to capturing and designing biologically active small molecules produced by uncultured microbes. Annu Rev Microbiol 65: 431–453.
16. Bergmann S, Schumann J, Scherlach K, Lange C, Brakhage AA, et al. (2007) Genomics-driven discovery of PKS-NRPS hybrid metabolites from Aspergillus nidulans. Nat Chem Biol 3: 213–217.
17. Wenkel SC, Muller R (2005) Formation of novel secondary metabolites by bacterial multimodular assembly lines: deviations from textbook biosynthetic logic. Curr Opin Chem Biol 9: 447–458.
18. Pullen CB, Schmitz P, Hoffmann D, Meurer K, Boetcher T, et al. (2003) Occurrence and non-detectability of maytansinoids in individual plants of the genera Maytenus and Putterliclia. Phytochemistry 62: 377–387.
19. Schroeckh V, Scherlach K, Nutzmann HW, Shelest E, Schmidt-Heck W, et al. (2009) Intimate bacterial-fungal interaction triggers biosynthesis of archetypal polyketides in Aspergillus nidulans. Proc Natl Acad Sci U S A 106: 14538–14563.
20. Baltz RH (2008) Renaissance in antibacterial discovery from actinomycetes. Curr Opin Pharmacol 8: 557–563.
21. Sayers EW, Barrett T, Benson DA, Bryant SH, Canese K, et al. (2009) Database resources of the National Center for Biotechnology Information. Nucleic Acids Res 37: D5–15.
22. Clardy J, Fischbach MA, Walsh CT (2006) New antibiotics from bacterial natural products. Nat Biotechnol 24: 1541–1550.
23. Dann JG, Stammers DK, Harris CJ, Arrowsmith RJ, Davies DE, et al. (1986) Human renin: a new class of inhibitors. Biochem Biophys Res Commun 134: 71–77.
24. Furet P, Caravatti G, Lydon N, Priestle JP, Sowadski JM, et al. (1995) Modelling study of protein kinase inhibitors: binding mode of staurosporine and origin of the selectivity of CGP 52411. J Comput Aided Mol Des 9: 463–472.
25. Adachi K, Kohara T, Nakao N, Arita M, Chiba K, et al. (1995) Design, synthesis, and structure-activity relationships of 2-substituted-2-amino-1,3-propanediol: Discovery of a novel immunosuppressant, FTY720. Bioorganic & Medicinal Chemistry Letters 5: 853–856.
26. Hunt JT (2009) Discovery of ixabepilone. Med Cancer Ther 8: 275–281.
27. Kingston DG (2009) Tubulin-interactive natural products as anticancer agents. J Nat Prod 72: 507–515.
28. Wall ME, Wani MC (1995) Camptothecin and taxol: discovery to clinic—thirteenth Bruce F. Cain Memorial Award Lecture. Cancer Res 55: 753–760.
29. Gambacorti-Passerini C (2008) Part I: Milestones in personalised medicine–imatinib. Lancet Oncol 9: 600.
30. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, et al. (1996) Effects of a selective inhibitor of the Ab1 tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2: 561–566.
31. Lydon NB, Druker BJ (2004) Lessons learned from the development of imatinib. Leuk Res 28 Suppl 1: S29–38.
32. Roberts NA, Martin JA, Kinchington D, Broadhurst AV, Craig JC, et al. (1990) Rational design of peptide-based HIV protease inhibitors. Science 248: 358–361.
33. McQuade TJ, Tomasselli AG, Liu L, Karacostas V, Moss B, et al. (1990) A synthetic HIV-1 protease inhibitor with antiviral activity arrests HIV-like particle maturation. Science 247: 454–456.
34. Ralph RK, McCombs PJ, Tener G, Wojcik SJ (1972) Evidence for modification of protein phosphorylation by cytokinins. Biochem J 130: 901–911.
35. Vesely J, Havlicek L, Straub M, Blow JJ, Donella-Deana A, et al. (1994) Inhibition of cyclin-dependent kinases by purine analogues. Eur J Biochem 224: 721–786.
36. Traxler PM, Furet P, Mert H, Buchdunger E, Meyer T, et al. (1996) 4-(Phenylamino)pyrrolopyrimidines: potent and selective, ATP site directed inhibitors of the EGF-receptor protein tyrosine kinase. J Med Chem 39: 2205–2209.
37. Nakano H, Omura S (2009) Chemical biology of natural indolocarbazole products: 30 years since the discovery of staurosporine. J Antibiot (Tokyo) 62: 17–26.